Moleculin Biotech (MBRX) Stock Rating Upgraded by Zacks Investment Research
Moleculin Biotech (NASDAQ:MBRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm currently has a $2.00 target price on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 15.61% from the stock’s previous close.
According to Zacks, “Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. “
Separately, ValuEngine raised Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings data on Tuesday, May 15th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. equities research analysts predict that Moleculin Biotech will post -0.57 EPS for the current year.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.